Trial Profile
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive (DLBCL and MCL) B-cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Mar 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Obinutuzumab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms GALEN; Lysa
- 16 Mar 2023 Status changed from active, no longer recruiting to completed.
- 05 Jun 2022 This trial has been completed in Belgium (End Date: 20 May 2022) according to European Clinical Trials Database record.
- 06 Apr 2022 Planned End Date changed from 1 Mar 2022 to 1 Dec 2022.